Fumarates: Unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine

Journal of Critical Care

Volumn 24, Issue 1, 2009, Pages 50-57

  Lien, Cynthia A ^a   Savard, Peter ^a   Belmont, Matthew ^a   Sunaga, Hiorshi ^a   Savarese, John J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRACURIUM; CISATRACURIUM; CW 002; CYSTEINE; EDROPHONIUM; GANTACURIUM; MIVACURIUM; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; SUXAMETHONIUM; UNCLASSIFIED DRUG;

DRUG ANTAGONISM; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; HEMODYNAMICS; HUMAN; NEUROMUSCULAR BLOCKING; NONHUMAN; REVIEW;

ANESTHESIA RECOVERY PERIOD; ANIMALS; ATRACURIUM; CATS; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; CYSTEINE; DOGS; DRUG EVALUATION, PRECLINICAL; FUMARATES; HAPLORHINI; HEMODYNAMICS; HUMANS; ISOQUINOLINES; METABOLIC CLEARANCE RATE; NEUROMUSCULAR NONDEPOLARIZING AGENTS; SAFETY; STEREOISOMERISM; TIME FACTORS;

EID: 61449132443     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2008.11.001     Document Type: Review

References (25)

1. Savarese J.J., and Kitz R.J. Does clinical anesthesia need new neuromuscular blocking agents?. Anesthesiology 42 (1975) 236-239
2. Berg H, Roed J, Viby Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 41:1095-1103;41.
3. Murphy G.S., Szokol J.W., Marymont J.H., Greenberg S.B., Avram M.J., and Vender J.S. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 107 (2008) 130-137
4. Boros E.E., Bigham E.C., Mook R.A., et al. Bis- and mixed-tetrahydroisoquinolinium chlorofumarates: new ultra-short-acting nondepolarizing neuromuscular blockers. J Med Chem 42 (1999) 206-209
5. Samano V., Ray J.A., Thompson J.B., et al. Synthesis of ultra-short-acting neuromuscular blocker GW 0430: A remarkably stereo- and regioselective synthesis of mixed tetrahydroisoquinolinium chlorofumarates. Org Lett 1 (1999) 1993-1996
6. Boros E.E., Samano V., Ray J.A., et al. Neuromuscular blocking activity and therapeutic potential effect of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys. J Med Chem 46 (2003) 2502-2515
7. Haijan Z., and Sacchetti M. Solid state characterization of an neuromuscular blocking agent-GW280430A. Int J Pharm 234 (2002) 19-23
8. Boros E.E., Samano V., Ray J.A., Thompson J.B., Jung D.K., Kaldor I., et al. Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys. J Med Chem 46 (2003) 2502-2515
9. Savarese J.J., Belmont M.R., Hashim M.A., et al. Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat. Anesthesiology 100 (2004) 835-845
10. Belmont M.R., Lien C.A., Tjan J., Bradley E., Stein B., Patel S.S., et al. Clinical pharmacology of GW280430A in humans. Anesthesiology 100 (2004) 768-773
11. Belmont M.R., Lien C.A., Savarese J.J., Patel S., Fisher G., and Mook R. Neuromuscular blocking effects of GW280430Aat the adductor pollicis and larynx in human volunteers. Br J Anaesth 82 (1999) A419
12. Cronnelly R., Morris R.B., and Miller R.D. Edrophonium: duration of action and atropine requirements in humans during halothane anesthesia. Anesthesiology 57 (1982) 261-266
13. Belmont M.R., Horochiwsky Z., Eliazo R.F., and Savarese J.J. Reversal of AV430A with cysteine in rhesus monkeys. Anesthesiology (2004) A1180
14. Heerdt P.M., Kang R., Andrew T., Hashim M., Mook R.J., and Savarese J.J. Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs. Anesthesiology 100 (2004) 846-851
15. Glaxo Wellcome Report No. RD2000/0016/00: A novel formulation-based approach to inhibition of GW280A-induced histamine release. Submitted as part of an IND Annual Report. 09 April 2002 (Serial Np. 008).
16. Belmont M.R., Lien C.A., Tjan J., and Patel S. Preliminary cardiovascular safety profile of AV430A in human volunteers. Anesthesiology 101 (2004) A1145
17. Savarese J.J., Belmont M.R., Cohn D.L., et al. Some SAR among isoquinolinium fumarate diesters leading to identification of AV 002. Anesthesiology 107 (2007) A386
18. Belmont M.R., Savard P., Vasquez A., et al. A promising cysteine-reversible intermediate duration neuromuscular blocker in rhesus monkeys. Anesthesiology 107 (2007) A986
19. Savard P.M.C., Belmont M.R., Cross W.M., et al. Comparative reversal of AV002 with cysteine and glutathione versus neostigmine in rhesus monkeys. Anesthesiology 107 (2007) A987
20. Beattie W.S., Buckley D.N., and Forrest J.B. Continuous infusions of atracurium and vecuronium, compared with intermittent boluses of pancuronium: dose requirements and reversal. Can J Anaesth 39 (1992) 925-931
21. Beemer G.H., Goonetilleke P.H., and Bjorksten A.R. The maximum depth of an atracurium neuromuscular block antagonized by edrophonium to effect adequate recovery. Anesthesiology 82 (1995) 852-858
22. Savarese J.J., Belmont M.R., Kraus K., et al. The new intermediate-duration nondepolarizing relaxant AV 002 has high autonomic safety in the cat. Anesthesiology 107 (2007) A984
23. Muir A.W., Sleigh T., Marshall R.J., et al. Neuromuscular blocking and cardiovascular effects of ORG 9487, a new short-acting aminosteroidal blocking agent, in anesthetized animals and in isolated muscle preparations. Eur J Anesthesiol 15 (1998) 467-479
24. Heerdt P.M., Malhotra J.K., Pan B.Y., et al. Cardiopulmonary effects of the novel neuromuscular blocking drug AV 002 in the dog. Anesthesiology 107 (2007) A983
25. Belmont M.R., Savard P., Cross W.M., et al. The hemodynamic profile of increasing doses of AV 002 in rhesus monkeys. Anestheisology 107 (2007) A387